IN2012DN03817A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03817A
IN2012DN03817A IN3817DEN2012A IN2012DN03817A IN 2012DN03817 A IN2012DN03817 A IN 2012DN03817A IN 3817DEN2012 A IN3817DEN2012 A IN 3817DEN2012A IN 2012DN03817 A IN2012DN03817 A IN 2012DN03817A
Authority
IN
India
Prior art keywords
treatment
biomarkers
inhibitor
proliferative
predict
Prior art date
Application number
Other languages
English (en)
Inventor
Denis Drygin
Sean O'brien
Kenna Anderes
Daniel D Vonhoff
John K C Lim
Claire S Padgett
Joshua R Bliesath
Caroline B Ho
William G Rice
Adam Siddiqui-Jain
Original Assignee
Cylene Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals filed Critical Cylene Pharmaceuticals
Publication of IN2012DN03817A publication Critical patent/IN2012DN03817A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G01N33/575
    • G01N33/57515
    • G01N33/57555
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IN3817DEN2012 2009-10-02 2010-10-04 IN2012DN03817A (enExample)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24827009P 2009-10-02 2009-10-02
US25580509P 2009-10-28 2009-10-28
US32377110P 2010-04-13 2010-04-13
US38068510P 2010-09-07 2010-09-07
PCT/US2010/051341 WO2011041785A1 (en) 2009-10-02 2010-10-04 Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors

Publications (1)

Publication Number Publication Date
IN2012DN03817A true IN2012DN03817A (enExample) 2015-08-28

Family

ID=43128291

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3817DEN2012 IN2012DN03817A (enExample) 2009-10-02 2010-10-04

Country Status (11)

Country Link
US (1) US20110212845A1 (enExample)
EP (1) EP2483686A1 (enExample)
JP (1) JP2013506836A (enExample)
KR (1) KR20120104196A (enExample)
AU (1) AU2010300307A1 (enExample)
BR (1) BR112012007555B1 (enExample)
CA (1) CA2776278A1 (enExample)
IL (1) IL218935A0 (enExample)
IN (1) IN2012DN03817A (enExample)
MX (1) MX2012003997A (enExample)
WO (1) WO2011041785A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201212773D0 (en) * 2012-07-18 2012-08-29 Ucl Business Plc Vascular remodelling
US9146545B2 (en) 2012-11-27 2015-09-29 Honeywell International Inc. Multivariable control system for setpoint design
TWI582239B (zh) * 2013-03-11 2017-05-11 諾華公司 與wnt抑制劑相關之標記
KR101593595B1 (ko) * 2013-10-08 2016-02-12 한국생명공학연구원 Cx-4945를 유효성분으로 함유하는 스플라이싱 조절제
WO2015053452A1 (ko) * 2013-10-08 2015-04-16 한국생명공학연구원 Cx-4945를 유효성분으로 함유하는 스플라이싱 조절제
US20170051062A1 (en) * 2014-02-18 2017-02-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
MX375557B (es) * 2014-07-18 2025-03-06 Sanofi Sa Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer.
WO2016133860A1 (en) * 2015-02-16 2016-08-25 Board Of Regents Of The University Of Nebraska Cancer biomarkers and methods of use thereof
GB202102895D0 (en) * 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2023190820A1 (ja) * 2022-03-30 2023-10-05 公立大学法人福島県立医科大学 抗CK2α抗体又はその断片
CN115160341B (zh) * 2022-07-18 2023-07-18 中国医学科学院医学实验动物研究所 苯并噁嗪类化合物及其药物用途
KR102641010B1 (ko) * 2023-12-04 2024-02-28 대한민국 실미타세르팁을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200715636A (en) 2005-10-04 2007-04-16 Antig Tech Co Ltd Method of controlling fuel concentration used in direct liquid fuel cell
ES2528316T3 (es) 2006-09-01 2015-02-06 Senhwa Biosciences, Inc. Moduladores de la serina-treonina proteína quinasa y de PARP
US8488289B2 (en) 2006-09-27 2013-07-16 International Rectifier Corporation Current protection circuit for intelligent power switch
US20090035609A1 (en) 2007-07-31 2009-02-05 Apple Inc. Intelligent universal rechargeable batteries for battery charging system for mobile and accessory devices

Also Published As

Publication number Publication date
JP2013506836A (ja) 2013-02-28
BR112012007555B1 (pt) 2020-09-29
IL218935A0 (en) 2012-07-31
US20110212845A1 (en) 2011-09-01
WO2011041785A1 (en) 2011-04-07
BR112012007555A2 (pt) 2016-10-25
CA2776278A1 (en) 2011-04-07
MX2012003997A (es) 2012-07-25
EP2483686A1 (en) 2012-08-08
KR20120104196A (ko) 2012-09-20
AU2010300307A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
IN2012DN03817A (enExample)
WO2015031808A3 (en) Diagnostic methods and compositions for treatment of glioblastoma
PH12012501581A1 (en) Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
MX2012001716A (es) Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
GB2463401B (en) Characterizing prostate disorders by analysis of microvesicles
EP4349248A3 (en) Apparatus for determining damaged tissue using sub-epidermal moisture measurements
MX2010006854A (es) Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
HK1208470A1 (en) Biomarkers for use in integrin therapy applications
BR112013030606A2 (pt) biomarcadores para terapia inibidora de hedgehog
DK1846424T3 (da) Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf
MX2014001246A (es) Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
HK1223795A1 (zh) 拉喹莫德响应性的基因表达生物标志物
NZ630026A (en) Inhibition of the glycine cleavage system for treatment of cancer
CO6680668A2 (es) Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor
WO2015172085A3 (en) Biomarkers for response to pi3k inhibitors
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
TR201907241T4 (tr) IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2.
MX2015009392A (es) Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias.
PH12019501942A1 (en) Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
UA118658C2 (uk) СПОСІБ ДІАГНОСТИКИ ПРОГНОЗУ ВІДПОВІДІ НА ІНГІБІТОР TNFα
EA201171178A1 (ru) Устройство и способ для определения и количественного анализа аналитов, в частности, микотоксинов
MX384423B (es) Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2).
NZ738389A (en) Inhibitor of igfbp3/tmem219 axis and diabetes
MX360932B (es) Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
WO2012068464A3 (en) Methods of treating and preventing thrombotic diseases using ask1 inhibitors